Abstract: The invention relates to fusion proteins and uses thereof for obtaining and isolating enriched populations of immune cells. Exemplified fusion proteins include those comprising a dysfunctional purinergic P2X7 receptor (P2X7R) epitope moiety and a Fc region of an antibody.

Abstract: The present invention relates to therapeutics, compositions, kits and methods of treatment comprising: (a) an immune cell or progenitor thereof, expressing a receptor comprising an antigen-recognition domain and a signalling domain, wherein the antigen-recognition domain binds to a tumour-specific antigen, preferably a dysfunctional P2X7 receptor, expressed on a cell surface; and (b) a bridging molecule comprising: (i) a targeting moiety that binds to a cell surface molecule on a target cell; and (ii) a tumour-specific epitope moiety, preferably a dysfunctional P2X7 receptor epitope moiety, that is bound by the antigen recognition domain.

Abstract: The present invention relates to methods for inhibiting the activity of a cellular immunotherapeutic in a subject who has received or is receiving a therapy with a cellular immunotherapeutic for binding to a target antigen, the method comprising: providing a subject who has received or is receiving a therapy with a cellular immunotherapeutic for binding to a target antigen; administering to the subject, a molecule for binding to the cellular immunotherapeutic, the molecule comprising or consisting of an epitope of the target antigen; wherein the epitope on the molecule competes with an epitope on the target antigen, for binding to the cellular immunotherapeutic and the molecule thereby disrupts the interaction between the cellular immunotherapeutic and the target antigen; thereby inhibiting the activity of the cellular immunotherapeutic in the subject.

Abstract: The present invention relates to novel antigen binding proteins for binding to dysfunctional P2X7 receptor.

Abstract: The present invention relates to compositions and methods or uses of those compositions for amplifying immune activity to treat a variety of diseases or conditions, particularly cancer. A method for treating a condition comprising administering to a subject an antigen binding protein comprising (i) a first antigen binding domain that binds to a tumour-specific antigen; and (ii) a second antigen binding domain that binds to a cell surface molecule on an immune cell, thereby treating the condition. Preferably, further comprising a bridging molecule comprising (i) a targeting moiety that binds to a cell surface molecule on a target cell; and (ii) a tumour-specific antigen epitope moiety that is bound by the first antigen binding domain of the antigen binding protein.

Abstract: The present invention provides an extracellular anti-linker/label epitope chimeric antigen receptor (anti-LLE CAR) comprising I) a linker/label epitope (LLE) binding domain, II) a transmembrane domain, and III) a signal transduction domain, wherein said extracellular LLE binding domain binds a target cell binding molecule (TCBM) comprising i) an antigen binding moiety (ABM), wherein said ABM binds specifically to an antigen expressed on a target cell, ii) a label moiety (LaM), wherein said LaM is a naturally occurring molecule in a subject or a derivative thereof, iii) a linker moiety (LiM) conjugating said ABM and said LaM, thereby forming a linker/label epitope (LLE), wherein said extracellular LLE binding domain binds said LLE with a higher preference than said naturally occurring molecule.

Abstract: A medicament can include a product for in vivo expression of a protein in a living being. The product can include a first entity, which includes a nucleic acid encoding an intracellularly expressible protein, and an associated second entity configured for specific binding to a cellular structure of the living being. One example of the product is a nucleotide-modified mRNA, in which includes a first ribonucleotide sequence encoding the intracellularly expressible protein, and a second ribonucleotide sequence encoding an aptamer configured for specific binding to the cellular structure of the living being.